The estimated Net Worth of Patricia A Bradford is at least $11.3 millier dollars as of 7 February 2011. Patricia Bradford owns over 581 units of Phio Pharmaceuticals stock worth over $11,339 and over the last 20 years Patricia sold PHIO stock worth over $0.
Patricia has made over 9 trades of the Phio Pharmaceuticals stock since 2007, according to the Form 4 filled with the SEC. Most recently Patricia exercised 581 units of PHIO stock worth $1,621 on 7 February 2011.
The largest trade Patricia's ever made was exercising 5,815 units of Phio Pharmaceuticals stock on 7 February 2009 worth over $16,224. On average, Patricia trades about 1,072 units every 69 days since 2005. As of 7 February 2011 Patricia still owns at least 4,064 units of Phio Pharmaceuticals stock.
You can see the complete history of Patricia Bradford stock trades at the bottom of the page.
Patricia's mailing address filed with the SEC is C/O PHIO PHARMACEUTICALS CORP., 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH, MA, 01752.
Over the last 6 years, insiders at Phio Pharmaceuticals have traded over $0 worth of Phio Pharmaceuticals stock and bought 37,351 units worth $53,368 . The most active insiders traders include Geert Cauwenbergh, Keith L Brownlie et Patricia A Bradford. On average, Phio Pharmaceuticals executives and independent directors trade stock every 82 days with the average trade being worth of $6,130. The most recent stock trade was executed by Robert J Bitterman on 7 June 2024, trading 1,000 units of PHIO stock currently worth $740.
Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Phio Pharmaceuticals executives and other stock owners filed with the SEC include: